MMSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Merit Medical Systems Inc (MMSI) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial growth in Q4 2025, the technical indicators are bearish, and recent analyst downgrades highlight concerns about future growth and guidance uncertainty. Additionally, there are no significant positive catalysts or trading signals to suggest immediate upside potential. Holding off on investment until clearer growth catalysts emerge or technical indicators improve is advisable.
The technical indicators for MMSI are bearish. The MACD histogram is negative (-0.3) and contracting, suggesting weak momentum. The RSI is neutral at 29.238, not indicating oversold conditions. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below its pivot level of 70.403, with key support at 67.907 and resistance at 72.9.
The company's Q4 2025 financials were strong, with revenue increasing by 10.92% YoY, net income up 35.99% YoY, and EPS up 36.96% YoY. Gross margin also improved to 49.59%.
Recent analyst downgrades, including Wells Fargo lowering its rating to Equal Weight and reducing the price target to $78 from $95, cite uncertainty in fiscal 2026 guidance and lack of growth catalysts. Additionally, the technical indicators are bearish, and there is no recent news or significant trading activity from insiders, hedge funds, or Congress to suggest a positive sentiment shift.
In Q4 2025, Merit Medical Systems reported strong financial performance with revenue of $393.9M (up 10.92% YoY), net income of $38M (up 35.99% YoY), EPS of $0.63 (up 36.96% YoY), and gross margin of 49.59% (up 1.81% YoY).
Analyst sentiment is mixed but leaning negative. Wells Fargo downgraded the stock to Equal Weight with a reduced price target of $78, citing guidance uncertainty and lack of catalysts. However, Barrington raised its price target to $109, and BTIG initiated coverage with a Buy rating and a $107 price target, citing the company's strong product portfolio and attractive valuation.
